Free tool
FAERS Monitor: Exparel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022496 or its brand name (Exparel, Bupivacaine). Reports on generic versions are filed under their own applications.
Reports
9,403
Serious
7,042
75% of reports
Hospitalization
2,776
Death reported
592
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use905
- pain772
- drug ineffective736
- hypotension548
- nausea414
- hypoaesthesia381
- maternal exposure during pregnancy379
- exposure during pregnancy336
- drug withdrawal syndrome281
- vomiting275
- maternal exposure during delivery258
- labelled drug-drug interaction medication error250
- overdose235
- foetal exposure during pregnancy229
- dyspnoea217
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 182 |
| 2005 | 132 |
| 2006 | 187 |
| 2007 | 152 |
| 2008 | 206 |
| 2009 | 224 |
| 2010 | 6 |
| 2011 | 11 |
| 2012 | 135 |
| 2013 | 394 |
| 2014 | 398 |
| 2015 | 294 |
| 2016 | 614 |
| 2017 | 657 |
| 2018 | 646 |
| 2019 | 772 |
| 2020 | 912 |
| 2021 | 631 |
| 2022 | 683 |
| 2023 | 675 |
| 2024 | 543 |
| 2025 | 648 |
| 2026 | 301 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,756 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| maternal exposure during deliverySignal | 258 | 787.8 | 684.5 | 149,373 |
| labelled drug-drug interaction medication errorSignal | 250 | 65.1 | 57.5 | 15,268 |
| exposure during pregnancySignal | 336 | 12.2 | 10.9 | 3,419 |
| maternal exposure during pregnancySignal | 379 | 9.5 | 8.6 | 2,892 |
| drug withdrawal syndromeSignal | 281 | 7.2 | 6.4 | 1,491 |
| foetal exposure during pregnancySignal | 229 | 6.3 | 5.6 | 1,021 |
| hypotensionSignal | 548 | 6.1 | 5.6 | 2,361 |
| hypoaesthesiaSignal | 381 | 5.7 | 5.2 | 1,481 |
| painSignal | 772 | 2.8 | 2.6 | 926 |
| overdoseSignal | 235 | 2.4 | 2.1 | 200 |
| off label useSignal | 905 | 2.3 | 2.2 | 702 |
| vomiting | 275 | 1.3 | 1.2 | 20 |
| drug ineffective | 736 | 1.2 | 1.2 | 39 |
| nausea | 414 | 1.2 | 1.1 | 10 |
| dyspnoea | 217 | 0.9 | 0.8 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.